Skip to main content
Clinical Trials/NL-OMON21253
NL-OMON21253
Recruiting
Not Applicable

Biomarkers in Atopic Dermatitis, The Netherlands

Amsterdam UMC, Academic Medical Center0 sites110 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
<p>Atopic dermatitis, atopic eczema</p>
Sponsor
Amsterdam UMC, Academic Medical Center
Enrollment
110
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Sponsor
Amsterdam UMC, Academic Medical Center

Eligibility Criteria

Inclusion Criteria

  • Patient has a diagnosis of AD, based on the U.K. working party’s diagnostic criteria;
  • \-Starts with any type of phototherapy (e.g. UVB) or systemic immunomodulating therapy (e.g. ciclosporin, systemic glucocorticosteroids, azathioprine, methotrexate, mycophenolic acid, dupilumab);
  • \-Has voluntarily signed and dated an informed consent prior to any study related procedure or has a legal representative to do so and is willing to comply with the requirements of this study protocol.

Exclusion Criteria

  • \-Patient uses only (systemic) antibiotics or antihistamines;
  • \-Patient starts with systemic immunomodulating therapy for another indication than atopic dermatitis;
  • \-Insufficient understanding of the study by the patient or parent/legal representative;
  • \-Patient does not participate in the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Biomarkers in Atopic Dermatitis and Psoriasis The NetherlandsAtopic dermatitisatopic eczema10014982
NL-OMON48036Academisch Medisch Centrum110
Active, not recruiting
Not Applicable
AMBITIOUSAtopic Dermatitis Biomarker Identification Trial in Omalizumab UsageSingle- arm trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitis - AMBITIOUSAMBITIOUS is a trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitisAtopische Dermatitis is a common inflammatory skin disease showing chronically relapsing eczema and high association with elevated serum IgE levels.MedDRA version: 14.0Level: LLTClassification code 10029264Term: Neurodermatitis aggravatedSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2010-018559-84-DEMedizinische Fakultät der technischen Universität Muenchen20
Active, not recruiting
Not Applicable
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)Dermatitis Atopic
NCT03849716Sanofi266
Completed
Not Applicable
Observation of atopic dermatitis in high-performance shower heads with a general shower head as a control Double-blind randomized trialAtopic dermatitis
JPRN-UMIN000041204Takashima Clinic57
Recruiting
Not Applicable
EVALUATION OF BIOMARKERS OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT MEDICALLY ADVISABLE
NL-OMON48261Sanofi-aventis12